Does Rallies show 13F holders for AZN?

Yes. Rallies tracks hedge fund and 13F ownership data for AZN, including fund names, share counts, latest tracked quarter, and position changes when available.

Is AZN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AZN. It does not provide personalized investment advice.

AZN (AstraZeneca PLC) Stock Analysis - Hedge Fund Holdings

AstraZeneca PLC (AZN) is a publicly traded Healthcare sector company. As of May 20, 2026, AZN trades at $187.48 with a market cap of $285.23B and a P/E ratio of 0.00. AZN moved +1.54% today. Year to date, AZN is +101.64%; over the trailing twelve months it is +164.94%. Its 52-week range spans $61.24 to $212.71. Analyst consensus is strong buy with an average price target of $214.28. Rallies surfaces AZN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns AZN stock?

Hedge funds tracked by Rallies that own AZN include Harris Associates, Soros Fund, Orbimed Advisors, Bridgewater Associates, and Temasek Holdings. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for AstraZeneca PLC.

AZN Key Metrics

Key financial metrics for AZN
Metric	Value
Price	$187.48
Market Cap	$285.23B
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	1.59%
52-Week High	$212.71
52-Week Low	$61.24
Volume	1.42M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Top Hedge Funds Holding AZN

Harris Associates holds 3.73M shares of AZN, changed +0.00% as of Dec 31, 2025.
Soros Fund holds 2.74M shares of AZN, changed -13.10% as of Mar 31, 2025.
Orbimed Advisors holds 670.20K shares of AZN, changed +0.00% as of Mar 31, 2026.
Bridgewater Associates holds 462.86K shares of AZN, changed -25.45% as of Sep 30, 2025.
Temasek Holdings holds 365.55K shares of AZN, changed +0.00% as of Mar 31, 2026.

Latest AZN News

AstraZeneca Gains FDA Approval for Baxfendy, Targets $5 Billion Hypertension Market — May 18, 2026
Primecap Cuts AstraZeneca Stake Representing 2.57% Portfolio Weight — May 11, 2026
FDA Panel Rejects AstraZeneca’s Camizestrant, Shares Drop 2% — May 1, 2026
Citi Raises AstraZeneca's 2026 EPS to $10.30, Sees Five Key Trials — Apr 30, 2026
AstraZeneca Pays $25M to License PTX-299 EGFR Degrader, Eyes $500M Milestones — Apr 29, 2026

AZN Analyst Consensus

15 analysts cover AZN: 0 strong buy, 13 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $214.28.

Common questions about AZN

Who owns AZN stock?: Hedge funds tracked by Rallies that own AZN include Harris Associates, Soros Fund, Orbimed Advisors, Bridgewater Associates, and Temasek Holdings. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for AstraZeneca PLC.
Does Rallies show 13F holders for AZN?: Yes. Rallies tracks hedge fund and 13F ownership data for AZN, including fund names, share counts, latest tracked quarter, and position changes when available.
Is AZN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AZN. It does not provide personalized investment advice.